GDTC CytoMed Therapeutics Limited: רווח למניה לשנה מתגלגלת

CytoMed Therapeutics is expanding the application of allogeneic T-cells to combat tumors. The annual volatility of net income per share TTM confirms this trajectory, where 3.80 serves as the base value of the parameter. The development of affordable NK-therapies reduces risks, while outsourcing trials to external CRO networks minimizes operating expenses, ensuring the stable growth of the Singaporean biotech business.
פילוחי מדדים פיננסיים ומדדי שוק עבור CytoMed (GDTC)

This indicator measures the annual growth rate of earnings per share over a rolling 12-month period, reflecting the efficiency of capitalizing innovations in T-cell therapy for oncology at CytoMed Therapeutics (GDTC). By analyzing the 12-month YoY EPS dynamics, an investor can assess the impact of hospital partnerships on profitability, given the metric's high sensitivity to currency fluctuations and development costs.